Shares of IMMUNEONCO-B (01541) rallied sharply during Tuesday afternoon trading, climbing nearly 12% at one point before settling at a 10.27% gain to HK$4.08, with turnover reaching HK$6.239 million. The surge came after the company released its interim results for the first half of 2026 on the evening of August 26, reporting revenue of RMB 25.424 million, primarily derived from payments received under a licensing and collaboration agreement with Axion Bio.

The company maintains a robust cash position, with cash and cash equivalents, financial assets measured at fair value, and time deposits with original maturities exceeding three months totaling approximately RMB 947 million as of June 30, 2026. During the reporting period, IMMUNEONCO-B continued to accelerate the development of its drug pipeline, achieving significant milestones in both oncology immunotherapy and autoimmune disease treatment.

Key clinical-stage assets, including IMM01 (Tidafuspt), IMM0306 (Amurifusp alpha), and IMM2510 (Povilafusp alpha), have made substantial progress, with multiple pivotal clinical trials reaching critical junctures. Meanwhile, the company is actively expanding beyond oncology into non-tumor therapeutic areas, making notable headway in autoimmune diseases, metabolic disorders, cardiovascular conditions, and pulmonary arterial hypertension, further unlocking the therapeutic potential of its candidate drugs.